(Q33405390)

English

A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Marcio H Malogolowkin

2

object named as

Marcio Malogolowkin

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Leo Mascarenhas

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Saro H Armenian

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Richard Sposto

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Rajkumar Venkatramani

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

17 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pediatric Blood Cancer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

60

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1103-1107

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Redefining the role of doxorubicin for the treatment of children with hepatoblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Ongoing and unsaid on oxaliplatin: the hope

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3815656

21 June 2018

Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24471

21 January 2018

A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24471

21 January 2018

Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24471

21 January 2018

Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlier

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24471

21 January 2018

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24471

21 January 2018

Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23335436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High risk of symptomatic cardiac events in childhood cancer survivors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23335436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin in treatment of malignant solid tumors in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/23335436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of daunorubicin (NSC-83142) with adriamycin (NSC-123127) in the treatment of late-stage childhood solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23335436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/23335436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/23335436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin: mechanism of action and antineoplastic activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23335436

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/PBC.24471

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33405390&oldid=1797639517"